Use of 852A in Metastatic Cutaneous Melanoma.

Inclusion Criteria:

• Advanced melanoma not responding to 1st line chemotherapy
• Histological evidence of melanoma
• Measurable disease according to RECIST criteria
• ECOG performance status less than or equal to 2
• Life expectancy 6 months or more
• Normal organ and bone marrow function as defined by hematological and serum chemistry limits
• Adequate contraception for females of childbearing potential

Exclusion Criteria:

• Stage IV disease which has previously progressed during interferon treatment.
• Restriction of some therapies/medications for a certain timeframe prior to enrollment and during the study including: investigational drugs, high dose corticosteroids, immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong QT interval and/or induce Torsades De Pointes
• History of uncontrolled seizure disorders
• Uncontrolled coagulation disorders.
• History or evidence of myocardial ischemia, congestive heart failure or arrythmias requiring treatment in the past 6 months
• History of uncontrolled intercurrent or chronic illness
• Concurrent malignancies.
• Brain metastases.
• HIV positive.
• Prolonged QTc interval
• Uncontrolled intercurrent or chronic illnesses.
• Pregnant or lactating women